Recently, China National Intellectual Property Administration issued the Notice of China National Intellectual Property Administration on Determining the New Batch of and Reviewed National Intellectual Property Demonstration Enterprises and Advantageous Enterprises in 2022, to determine the new batch of and reviewed national intellectual property demonstration enterprises and advantageous enterprises in 2022.

Biokin Pharmaceuticals was recognized as New Batch of National Intellectual Property Demonstration Enterprises. National Intellectual Property Demonstration Enterprise refers to a demonstration enterprise with strategic management concept of intellectual property, outstanding comprehensive competitive advantages in intellectual property, and industry influence and benchmark significance, which is the highest honor and appraisal given by the state to an enterprise's intellectual property management work. Since Biokin Pharmaceuticals was awarded National Intellectual Property Advantage Enterprise in 2016, it has made great progress in IP system construction and IP creation, application, protection and management, and has been successfully upgraded to National Intellectual Property Demonstration Enterprise. This marks the innovative R&D strength and IP management efficiency of Biokin Pharmaceuticals reaches a leading level in China.